MBX Biosciences (MBX) Change in Account Payables (2023 - 2026)

MBX Biosciences has reported Change in Account Payables for 4 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Change in Account Payables rose 353.96% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 63.05% YoY) and the FY2025 annual result came in at -$2.5 million, down 162.54% from the prior year.
• Change in Account Payables improved to $4.0 million in Q1 2026 per MBX's latest filing, from -$861000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.0 million in Q1 2026 and troughed at -$2.0 million in Q3 2025.
• A 4-year average of $513300.0 and a median of $526500.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables plunged 429.96% in 2025, then jumped 353.96% in 2026.
• Over 4 years, Change in Account Payables stood at -$310000.0 in 2023, then soared by 308.06% to $645000.0 in 2024, then tumbled by 233.49% to -$861000.0 in 2025, then soared by 561.32% to $4.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $4.0 million, -$861000.0, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.